ERT announced that it was awarded three new contracts with top tier pharmaceutical companies, totaling over $10 million for its electronic patient reported outcomes (ePRO) business. The company has been selected to provide its diverse multi-modality solutions.
ERT is gaining increasing market share in the ePRO market. ERT offers a broad range of ePRO solutions to collect accurate subject self-reports and real-time data during a clinical trial. The most significant ePRO award is an exclusive agreement with a specialty division of a top 5 pharmaceutical company that has selected ERT to manage a suite of studies using ERT’s proprietary VIAPhone platform over the next three years. The contract will be worth in excess of $7.0 million. The second award is part of a $3.0 million contract for which ERT will provide its VIAPen solution for a pivotal Phase III program. The third award has been secured with a top 10 pharmaceutical company who will be using ERT’s unique VIAPhone Pain Diary for use in a Phase III clinical trial, alongside its VIAPen solution for site assessments, as part of a $1.2 million contract.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.